Darmadi Darmadi, Dharma Lindarto, Jelita Siregar, Tri Widyawati, Muhammad Rusda, Mustafa Mahmud Amin, Fauzi Yusuf, Putri Chairani Eyanoer, Masrul Lubis, Imelda Rey
{"title":"慢性乙型肝炎患者血清细胞毒性T淋巴细胞抗原(CTLA)-4水平与疾病进展的关系","authors":"Darmadi Darmadi, Dharma Lindarto, Jelita Siregar, Tri Widyawati, Muhammad Rusda, Mustafa Mahmud Amin, Fauzi Yusuf, Putri Chairani Eyanoer, Masrul Lubis, Imelda Rey","doi":"10.5455/medarh.2023.77.142-145","DOIUrl":null,"url":null,"abstract":"<p><strong>Backgroud: </strong>Immune impairment, marked by increased expression of cytotoxic T lymphocyte antigen (CTLA)-4, promotes the disease progression of chronic hepatitis B.</p><p><strong>Objective: </strong>This study aimed to determine the association between serum CTLA-4 level and disease progression in patients with chronic hepatitis B.</p><p><strong>Methods: </strong>A cross-sectional study was conducted at Haji Adam Malik General Hospital Medan, Indonesia between October 2021 to September 2022. A total of 150 participants were enrolled. Patients aged 18 years or older with evidence of chronic hepatitis B, HBV-related liver cirrhosis, and HBV-related hepatocellular carcinoma (HCC) were enrolled. Exclusion criteria were history of chronic hepatotoxic drug consumption, underlying liver abnormalities other than HBV infection, and liver injury due to metastasized malignancy from other sites. Serum CTLA-4 level was determined from serum using human CTLA-4 enzyme linked immunosorbent assay kit.</p><p><strong>Results: </strong>Most participants were males and aged between 40 and 60 years. Serum CTLA-4 level was positively associated with chronic hepatitis B progression (P<0.001). Serum CTLA-4 level was negatively correlated with serum platelet (P<0.001) and albumin levels (P<0.001) but positively correlated with serum ALT (P=0.045) and total bilirubin levels (P<0.001).</p><p><strong>Conclusions: </strong>Serum CTLA-4 level is associated with disease progression in patients with chronic hepatitis B.</p>","PeriodicalId":18421,"journal":{"name":"Medicinski arhiv","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fb/65/medarch-77-142.PMC10227835.pdf","citationCount":"0","resultStr":"{\"title\":\"Association Between Serum Cytotoxic T Lymphocyte Antigen (CTLA)-4 Level and Disease Progression in Patients With Chronic Hepatitis B.\",\"authors\":\"Darmadi Darmadi, Dharma Lindarto, Jelita Siregar, Tri Widyawati, Muhammad Rusda, Mustafa Mahmud Amin, Fauzi Yusuf, Putri Chairani Eyanoer, Masrul Lubis, Imelda Rey\",\"doi\":\"10.5455/medarh.2023.77.142-145\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Backgroud: </strong>Immune impairment, marked by increased expression of cytotoxic T lymphocyte antigen (CTLA)-4, promotes the disease progression of chronic hepatitis B.</p><p><strong>Objective: </strong>This study aimed to determine the association between serum CTLA-4 level and disease progression in patients with chronic hepatitis B.</p><p><strong>Methods: </strong>A cross-sectional study was conducted at Haji Adam Malik General Hospital Medan, Indonesia between October 2021 to September 2022. A total of 150 participants were enrolled. Patients aged 18 years or older with evidence of chronic hepatitis B, HBV-related liver cirrhosis, and HBV-related hepatocellular carcinoma (HCC) were enrolled. Exclusion criteria were history of chronic hepatotoxic drug consumption, underlying liver abnormalities other than HBV infection, and liver injury due to metastasized malignancy from other sites. Serum CTLA-4 level was determined from serum using human CTLA-4 enzyme linked immunosorbent assay kit.</p><p><strong>Results: </strong>Most participants were males and aged between 40 and 60 years. Serum CTLA-4 level was positively associated with chronic hepatitis B progression (P<0.001). Serum CTLA-4 level was negatively correlated with serum platelet (P<0.001) and albumin levels (P<0.001) but positively correlated with serum ALT (P=0.045) and total bilirubin levels (P<0.001).</p><p><strong>Conclusions: </strong>Serum CTLA-4 level is associated with disease progression in patients with chronic hepatitis B.</p>\",\"PeriodicalId\":18421,\"journal\":{\"name\":\"Medicinski arhiv\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fb/65/medarch-77-142.PMC10227835.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicinski arhiv\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5455/medarh.2023.77.142-145\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicinski arhiv","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5455/medarh.2023.77.142-145","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
背景:以细胞毒性T淋巴细胞抗原(CTLA)-4表达增加为标志的免疫功能障碍促进慢性乙型肝炎的疾病进展。目的:本研究旨在确定慢性乙型肝炎患者血清CTLA-4水平与疾病进展之间的关系。方法:2021年10月至2022年9月在印度尼西亚棉兰Haji Adam Malik总医院进行横切性研究。总共有150名参与者被招募。年龄在18岁或以上且有慢性乙型肝炎、hbv相关肝硬化和hbv相关肝细胞癌(HCC)证据的患者被纳入研究。排除标准为慢性肝毒性药物使用史，HBV感染以外的潜在肝脏异常，以及其他部位恶性肿瘤转移引起的肝损伤。采用人CTLA-4酶联免疫吸附测定试剂盒测定血清CTLA-4水平。结果:大多数参与者为男性，年龄在40至60岁之间。血清CTLA-4水平与慢性乙型肝炎进展呈正相关(p结论:血清CTLA-4水平与慢性乙型肝炎患者疾病进展相关。
Association Between Serum Cytotoxic T Lymphocyte Antigen (CTLA)-4 Level and Disease Progression in Patients With Chronic Hepatitis B.
Backgroud: Immune impairment, marked by increased expression of cytotoxic T lymphocyte antigen (CTLA)-4, promotes the disease progression of chronic hepatitis B.
Objective: This study aimed to determine the association between serum CTLA-4 level and disease progression in patients with chronic hepatitis B.
Methods: A cross-sectional study was conducted at Haji Adam Malik General Hospital Medan, Indonesia between October 2021 to September 2022. A total of 150 participants were enrolled. Patients aged 18 years or older with evidence of chronic hepatitis B, HBV-related liver cirrhosis, and HBV-related hepatocellular carcinoma (HCC) were enrolled. Exclusion criteria were history of chronic hepatotoxic drug consumption, underlying liver abnormalities other than HBV infection, and liver injury due to metastasized malignancy from other sites. Serum CTLA-4 level was determined from serum using human CTLA-4 enzyme linked immunosorbent assay kit.
Results: Most participants were males and aged between 40 and 60 years. Serum CTLA-4 level was positively associated with chronic hepatitis B progression (P<0.001). Serum CTLA-4 level was negatively correlated with serum platelet (P<0.001) and albumin levels (P<0.001) but positively correlated with serum ALT (P=0.045) and total bilirubin levels (P<0.001).
Conclusions: Serum CTLA-4 level is associated with disease progression in patients with chronic hepatitis B.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
